Gateway 2026 Biosimilar Trends
What you need to know about market trends as the specialty pipeline expands and biosimilars reshape the cost picture. Get the report below.
-
-
The Future of Specialty Medications: What Employer Plans Need to Know
The pipeline for specialty and advanced therapies continues to expand. Gene therapies, targeted oncology treatment, and high-cost biologics are expected to significantly affect pharmacy benefits over the next decade. Employer-sponsored health plans should start preparing now for how they are going to handle these costs. The specialty market was $92.5 billion in 2023 and could…
-
5 Myths About Biosimilars
Biologic drugs are medicines that come from living organisms, like genes and proteins. Biologics make up about 5% of U.S. prescriptions, but more than 50% of total prescription drug spending in the country. Biosimilar drugs are biologic drugs that are highly similar compared to their reference products, which are existing biologics. Biosimilars are not exact…
-
-
Market Outlook: Drug Rebates and Net Cost Thinking
This year, the prescription drug landscape is shifting from a focus on rebates toward a more transparent view of net costs. For years, manufacturer rebates paid to pharmacy benefit managers (PBMs) have been key to drug pricing. These rebates were meant to lower overall spend but they sometimes hid the real costs paid by payers…
-
Direct-to-consumer Pricing: What It Could Mean for Rebates, Plan Costs, and Members
Direct-to-consumer (DTC) pricing for medications is making a splash. With DTC, drug manufacturers sell medications directly to patients instead of through a retail pharmacy or pharmacy benefit manager (PBM). This is a shift from the traditional pharmacy model. Some drugs, including those for weight management, now have a DTC model. Eli Lilly & Co. and…
-
GLP-1s for Weight Loss Outlook 2026
What’s ahead in the GLP-1 market in 2026 The obesity rate has been increasing over time in the U.S. From August 2021 to August 2023, about 40% of American adults were considered obese. A recent study shows that these rates will continue to rise for about 20 more years. Complications related to obesity include heart…
-
Market Outlook: Five Trends to Watch in 2026
From IRA implementation to the impacts of AMP Cap and biosimilar adoption, here are five market trends Gateway Health Partners is keeping an eye on as we head into 2026 and how we’re helping clients stay ahead as the market continues to evolve.
-
The Expansion of GLP-1 Medications
Beyond Diabetes and Obesity: The Expansion of GLP-1 Medications Glucagon-like peptide-1 (GLP-1) medications have revolutionized the treatment of diabetes and obesity, but their impact is rapidly broadening. Recent research and regulatory approvals reveal that GLP-1s may offer hope for a range of other health conditions, some of which might surprise you. Metabolic dysfunction-associated steatohepatitis (MASH)…
-
Optimize Your Savings: An In-Depth Look at Gateway’s ProOptimizer
As the rebate landscape evolves, with biosimilars gaining traction and legislation reshaping pricing dynamics, staying ahead means having the right technology in place. The right tools can change everything, and Gateway Health Partner’s ProOptimizer is built to help you succeed. From complexity to clarity. ProOptimizer exists to help clients simplify their reporting by breaking down…
